Aselizumab: A Detailed Investigation into HuDreg-55
Aselizumab, designated HuDreg-55, is a emerging monoclonal antibody designed to bind to complement protein . How it works relies get more info on disrupting the initial complement pathway
Aselizumab, designated HuDreg-55, is a emerging monoclonal antibody designed to bind to complement protein . How it works relies get more info on disrupting the initial complement pathway